Oscar Health Inc. (OSCR) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Oscar Health Inc. (OSCR) advanced +1.02% to $30.79 as options desks priced 53% call premium vs. 47% put protection around the $30 max-pain magnet. Solid 41% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Oscar Health (OSCR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
HAS, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on October 30th, 2026.
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $30.79, denoting a +1.02% move from the preceding trading day.
Oscar Health is broadening its growth beyond ACA insurance through Lucie and CHOICE, adding fee-based opportunities as its shares rise 116% year to date.
Oscar Health has turned into a headline stock over the past few years, and the share price now puts a sharp spotlight on what investors are actually paying for in terms of its earnings. With that kind of attention, the k
E, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on October 28th, 2026.
WOOF, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on October 26th, 2026.
Oscar Health, Inc. (OSCR) concluded the recent trading session at $30.99, signifying a -6.99% move from its prior day's close.
Oscar Health CEO Mark Bertolini explains why the lack of upfront, shoppable pricing in the healthcare industry is driving up costs—and how empowering consumers to make value-based choices could force the system to change
The major insurers are entering new Affordable Care Act markets as others are leaving the exchanges en masse, though in the cases of Centene and UnitedHealthcare, they paper over larger state exits.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +39.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OSCR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OSCR. Explore sector supply chains on /butterfly.
Why OSCR Stock advanced +1.02% Today — RQD Quant Desk Flash. Solid 41% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.